Calidi Biotherapeutics Inc. (CLDI)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $2.21M
Last updated: Nov 17, 2026 at 4:24 PM ET
Calidi Biotherapeutics Inc. (CLDI) Statistics
Calidi Biotherapeutics (CLDI) has a market cap of $2.21M. It holds $3.95M more cash than debt, 178.25% of its market cap. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
| Market Cap | $2.21M |
|---|---|
| Latest price (Nov 17, 2026) | $0.55 |
Key Dates
| Last Earnings Date | Nov 13, 2026 |
|---|---|
| Fiscal Year End | December |
Price Statistics
The stock is down 97.70% over 52 weeks and trades 39.56% below its 50-day average.
| Beta (1Y) | 2.55 |
|---|---|
| 52-Week Change | -97.70% |
| 1-Month Change | -29.65% |
| 3-Month Change | -60.07% |
| 6-Month Change | -81.28% |
| Total Return (1Y) | -97.70% |
| Total Return (3Y CAGR) | -94.63% |
| Total Return (5Y CAGR) | -87.63% |
| Max Drawdown (1Y) | -97.76% |
| Max Drawdown (3Y) | -99.99% |
| Sharpe Ratio (1Y) | -3.48 |
| Correlation with SPY (1Y) | 0.32 |
| 50-Day Average | $0.91 |
| 200-Day Average | $3.50 |
| 52-Week Range | $0.59 to $24.80 |
| RSI (14 Days) | 27.5 |
| Average Volume (20 Days) | 45.06K |
Financial Position
Current assets cover 1.27x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 1.27x |
|---|---|
| Quick Ratio | 1.27x |
| Debt / Equity | 0.00x |
| Interest Coverage | -105.59x |
Returns and Efficiency
Return on equity is -979.34% and return on assets is -289.21% over the last 12 months.
| Return on Equity (ROE) | -979.34% |
|---|---|
| Return on Assets (ROA) | -289.21% |
Scores
CLDI has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$423.00K |
| Operating Income | -$17.15M |
| Pretax Income | -$15.96M |
| Net Income | -$15.97M |
| EBITDA | -$14.35M |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 29.53% of the $5.52M in total assets.
| Cash and Equivalents | $3.95M |
|---|---|
| Total Debt | $0 |
| Net Cash | $3.95M |
| Net Cash Per Share | $1.59 |
| Working Capital | $1.01M |
| Shareholder Equity | $1.63M |
| Book Value Per Share | $0.66 |
| Total Assets | $5.52M |
| Total Liabilities | $3.89M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $91.00K of capital spending, operating cash flow left -$15.94M of free cash flow.
| Operating Cash Flow | -$15.85M |
|---|---|
| Capital Expenditures | $91.00K |
| Free Cash Flow | -$15.94M |
| FCF Per Share | -$4.34 |
| Depreciation and Amortization | $1.70M |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
CLDI does not pay a dividend. Its free cash flow yield is -1168.32%.
| FCF Yield | -1168.32% |
|---|---|
| Buyback Yield | -473.94% |
| Shareholder Yield | -473.94% |
Stock Splits
The last split was a 1-for-16 reverse split on Jul 31, 2026.
| Last Split Date | Jul 31, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:16 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CLDI
What is CLDI's market cap?
Calidi Biotherapeutics has a market cap of $2.21M.
How many shares of CLDI are outstanding?
Calidi Biotherapeutics has 2.48M shares outstanding.
Does CLDI pay a dividend?
No. Calidi Biotherapeutics does not pay a dividend.
How much debt does CLDI have?
Calidi Biotherapeutics has $0 of total debt and $3.95M of cash and equivalents, a net cash position of $3.95M.
CLDI pages: Overview, Charting, Earnings, Financials, Statistics, Competitors